BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27185374)

  • 21. Analysis of hypoxia in human glioblastoma tumors with dynamic 18F-FMISO PET imaging.
    Abdo RA; Lamare F; Fernandez P; Bentourkia M
    Australas Phys Eng Sci Med; 2019 Dec; 42(4):981-993. PubMed ID: 31520369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
    Szeto MD; Chakraborty G; Hadley J; Rockne R; Muzi M; Alvord EC; Krohn KA; Spence AM; Swanson KR
    Cancer Res; 2009 May; 69(10):4502-9. PubMed ID: 19366800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies.
    Cher LM; Murone C; Lawrentschuk N; Ramdave S; Papenfuss A; Hannah A; O'Keefe GJ; Sachinidis JI; Berlangieri SU; Fabinyi G; Scott AM
    J Nucl Med; 2006 Mar; 47(3):410-8. PubMed ID: 16513609
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: Comparison of intraindividually matched T1 - and T2 (*) -based bolus techniques.
    Bonekamp D; Deike K; Wiestler B; Wick W; Bendszus M; Radbruch A; Heiland S
    J Magn Reson Imaging; 2015 Jul; 42(1):87-96. PubMed ID: 25244574
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-resolution blood-pool-contrast-enhanced MR angiography in glioblastoma: tumor-associated neovascularization as a biomarker for patient survival. A preliminary study.
    Puig J; Blasco G; Daunis-I-Estadella J; Alberich-Bayarri A; Essig M; Jain R; Remollo S; Hernández D; Puigdemont M; Sánchez-González J; Mateu G; Wintermark M; Pedraza S
    Neuroradiology; 2016 Jan; 58(1):17-26. PubMed ID: 26438560
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Sep; 124(3):261-270. PubMed ID: 28734696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Effect of Neoadjuvant Androgen Deprivation Therapy on Tumor Hypoxia in High-Grade Prostate Cancer: An
    Mainta IC; Zilli T; Tille JC; De Perrot T; Vallée JP; Buchegger F; Garibotto V; Miralbell R
    Int J Radiat Oncol Biol Phys; 2018 Nov; 102(4):1210-1218. PubMed ID: 29678527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of DCE-MRI kinetic parameters and FMISO-PET uptake parameters in head and neck cancer patients.
    Simoncic U; Leibfarth S; Welz S; Schwenzer N; Schmidt H; Reischl G; Pfannenberg C; Fougère C; Nikolaou K; Zips D; Thorwarth D
    Med Phys; 2017 Jun; 44(6):2358-2368. PubMed ID: 28317128
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complementary information from magnetic resonance imaging and (18)F-fluoromisonidazole positron emission tomography in the assessment of the response to an antiangiogenic treatment in a rat brain tumor model.
    Valable S; Petit E; Roussel S; Marteau L; Toutain J; Divoux D; Sobrio F; Delamare J; Barré L; Bernaudin M
    Nucl Med Biol; 2011 Aug; 38(6):781-93. PubMed ID: 21843775
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer.
    Okamoto S; Shiga T; Yasuda K; Ito YM; Magota K; Kasai K; Kuge Y; Shirato H; Tamaki N
    J Nucl Med; 2013 Feb; 54(2):201-7. PubMed ID: 23321456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Changes in Tumor Biology During Chemoradiation of Cervix Cancer Assessed by Multiparametric MRI and Hypoxia PET.
    Georg P; Andrzejewski P; Baltzer P; Daniel M; Wadsak W; Mitterhauser M; Sturdza A; Majercakova K; Karanikas G; Pötter R; Hacker M; Helbich T; Georg D; Pinker K
    Mol Imaging Biol; 2018 Feb; 20(1):160-169. PubMed ID: 28540524
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lack of correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in non-small cell lung cancer assessed by 18F-Fluoromisonidazole and 18F-FDG PET.
    Cherk MH; Foo SS; Poon AM; Knight SR; Murone C; Papenfuss AT; Sachinidis JI; Saunder TH; O'Keefe GJ; Scott AM
    J Nucl Med; 2006 Dec; 47(12):1921-6. PubMed ID: 17138734
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
    Ly KI; Vakulenko-Lagun B; Emblem KE; Ou Y; Da X; Betensky RA; Kalpathy-Cramer J; Duda DG; Jain RK; Chi AS; Plotkin SR; Batchelor TT; Sorensen G; Rosen BR; Gerstner ER
    Sci Rep; 2018 Nov; 8(1):17062. PubMed ID: 30459364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison between perfusion computed tomography and dynamic contrast-enhanced magnetic resonance imaging in assessing glioblastoma microvasculature.
    Jia ZZ; Shi W; Shi JL; Shen DD; Gu HM; Zhou XJ
    Eur J Radiol; 2017 Feb; 87():120-124. PubMed ID: 28034567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of survival and progression in glioblastoma patients using temporal perfusion changes during radiochemotherapy.
    Larsson C; Groote I; Vardal J; Kleppestø M; Odland A; Brandal P; Due-Tønnessen P; Holme SS; Hope TR; Meling TR; Fosse E; Emblem KE; Bjørnerud A
    Magn Reson Imaging; 2020 May; 68():106-112. PubMed ID: 32004711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Applying a patient-specific bio-mathematical model of glioma growth to develop virtual [18F]-FMISO-PET images.
    Gu S; Chakraborty G; Champley K; Alessio AM; Claridge J; Rockne R; Muzi M; Krohn KA; Spence AM; Alvord EC; Anderson AR; Kinahan PE; Swanson KR
    Math Med Biol; 2012 Mar; 29(1):31-48. PubMed ID: 21562060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. 18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.
    Muzi M; Peterson LM; O'Sullivan JN; Fink JR; Rajendran JG; McLaughlin LJ; Muzi JP; Mankoff DA; Krohn KA
    J Nucl Med; 2015 Aug; 56(8):1223-8. PubMed ID: 26112020
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
    Paik W; Kim HS; Choi CG; Kim SJ
    Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival.
    Spence AM; Muzi M; Swanson KR; O'Sullivan F; Rockhill JK; Rajendran JG; Adamsen TC; Link JM; Swanson PE; Yagle KJ; Rostomily RC; Silbergeld DL; Krohn KA
    Clin Cancer Res; 2008 May; 14(9):2623-30. PubMed ID: 18451225
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Change in 18F-Fluoromisonidazole PET Is an Early Predictor of the Prognosis in the Patients with Recurrent High-Grade Glioma Receiving Bevacizumab Treatment.
    Yamaguchi S; Hirata K; Toyonaga T; Kobayashi K; Ishi Y; Motegi H; Kobayashi H; Shiga T; Tamaki N; Terasaka S; Houkin K
    PLoS One; 2016; 11(12):e0167917. PubMed ID: 27936194
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.